Long-Term Effects on Hypothalamic Neuropeptides after Developmental Exposure to Chlorpyrifos in Mice by Tait, Sabrina et al.
112  v o l u m e  117 | n u m b e r  1 | January 2009  •  Environmental Health Perspectives
Research
Long­term exposure to food and environ­
mental contaminants at dose levels devoid of 
systemic toxicity may nonetheless affect the 
function of target organs. This is of particu­
lar concern for in utero exposure, which can 
affect the fetal programming of critical tissues, 
thus representing a key risk factor for normal 
growth and development.
Organophosphorus (OP) insecticides such 
as chlorpyrifos (CPF), conventionally consid­
ered mainly as acetylcholinesterase (AChE) 
inhibitors, are potential endocrine­disrupting 
chemicals (EDCs) (Hodgson and Rose 2007; 
Meeker et al. 2006). CPF is still commonly used 
on agricultural crops; it was also widely used 
for urban pest control until the United States 
restricted residential use because of its devel­
opmental neurotoxicity (U.S. Environmental 
Protection Agency 2002). The main metabo­
lite, CPF oxon, prevents acetylcholine degra­
dation, thus acting as cholinesterase inhibitor 
(Dam et al. 1999a; Mileson et al. 1998; Slotkin 
2004), whereas CPF itself has a more general 
neurotoxic action, interfering with neural cell 
replication and differentiation and with synapse 
development and function (Casida and Quistad 
2004; Crumpton et al. 2000; Dam et al. 1999a; 
Roy et al. 1998; Slotkin 2004).
The association between developmental 
neurotoxicity and OP exposure in humans is 
a major environmental health issue. A recent 
study has shown for the first time that in utero 
CPF exposure, at subtoxic doses, is related 
to persistent behavioral effects in children, 
affecting different neuropsychologic domains, 
such as attention and social responses (Rauh 
et al. 2006). Findings in rodents indicate 
that CPF alters the functional maturation of 
neurotransmitter systems such as the dop­
aminergic and serotonergic systems (Aldridge 
et al. 2004, 2005b; Dam et al. 1999b; Raines 
et al. 2001; Slotkin et al. 2002), thus caus­
ing persistent neuro  behavioral abnormalities 
even at exposures well below the threshold for 
AChE inhibition (Barone et al. 2000; Carr 
et al. 2001; Dam et al. 2000; Icenogle et al. 
2004; Levin et al. 2001; Qiao et al. 2002, 
2003; Ricceri et al. 2003, 2006). In particular, 
the rat serotonergic system appears to be sensi­
tive to developmental disruption by CPF dur­
ing a selective window of exposure, from late 
gestation through the immediate post  natal 
period (Aldridge et al. 2005b). Interestingly, 
in mice, similarly to rats, the behavioral 
changes brought about by developmental CPF 
exposure are sexually dimorphic and involve 
associative functions, as well as sex­specific 
social responses (Ricceri et al. 2003, 2006). 
The long­term changes to the serotonergic 
system in multiple brain areas, in terms of up­
regulation of serotonin [5­hydroxy  tryptamine 
(5­HT)] receptors and transporters, are in 
line with the behavioral alteration so far evi­
denced, because 5­HT is markedly implicated 
in modulation of social behavior patterns in 
both sexes (Aldridge et al. 2004; Bell and 
Hobson 1994; Olazabal et al. 2004; Raines 
et al. 2001).
These same behavioral patterns are also 
regulated by hypothalamic peptides acting as 
hormones and neurotransmitters. Oxytocin 
(OT) and arginine vasopressin (AVP) are 
abundant cyclic neuropeptides of nine amino 
acids, differing only in two residues, predomi­
nantly expressed in magnocellular neurons 
in the hypothalamic paraventricular nuclei 
(PVN) and supraoptic nuclei (SON); both 
neuro  peptides are primarily involved in regu­
la  tion of physiologic functions, such as smooth 
muscle contraction, labor and lactation onset 
(OT), and homeo  stasis of blood pressure and 
water resorption (AVP) (Bielsky and Young 
2004; Gimpl and Fahrenholz 2001). In addi­
tion, increasing evidence points to their roles 
in neuro  behavioral responses: OT plays a 
key role in regulating social recognition and 
parental care in mammals (Bosch et al. 2006; 
Gimpl and Fahrenholz 2001; Keverne and 
Curley 2004), whereas AVP regulates social 
recognition, aggression, and learning and 
memory (Bielsky and Young 2004; Bosch 
et al. 2005; Caldwell et al. 2008; Keverne and 
Curley 2004).
Pituitary prolactin (PRL) exerts a number 
of functions on mammary glands, as well as on 
accessory glands of the reproductive system, 
Address correspondence to G. Calamandrei, Section 
of Neurotoxicology and Neuroendocrinology, 
Department of Cell Biology and Neurosciences, 
Istituto Superiore di Sanità, Viale Regina Elena 299, 
00161 Rome, Italy. Telephone: 39­06­4990­2106. 
Fax: 39­06­4957821. E­mail: gemma.calamandrei@
iss.it
We thank C. La Rocca and V. Lagatta for their 
technical support. 
This research was supported by the Net­
works  of  Excellence  CASCADE  contract 
FOOD­CT­2004­06319 and by Istituto Superiore 
di Sanità/National Institutes of Health project 0F14.
The authors declare they have no competing 
  financial interests.
Received 13 May 2008; accepted 22 August 2008.
Long-Term Effects on Hypothalamic Neuropeptides after Developmental 
Exposure to Chlorpyrifos in Mice
Sabrina Tait,1 Laura Ricceri,2 Aldina Venerosi,2 Francesca Maranghi,1 Alberto Mantovani,1 
and Gemma Calamandrei2
1Section of Food and Veterinary Toxicology, Department of Food Safety and Veterinary Public Health, and 2Section of Neurotoxicology 
and Neuroendocrinology, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy
Ba c k g r o u n d : Increasing evidence from animal and human studies indicates that chlorpyrifos 
(CPF), similar to other organophosphorus insecticides still widely used, is a developmental neuro-
toxicant. Developmental exposure to CPF in rodents induces sex-dimorphic behavioral changes at 
adulthood, including social and agonistic responses, which suggests that CPF may interfere with 
maturation of neuroendocrine mechanisms.
oB j e c t i v e s: We assessed the hypothesis that CPF affects the levels of neurohypophyseal hormones 
acting as modulators of social behavior in mammals, such as oxytocin (OT), arginine vasopressin 
(AVP), and prolactin (PRL).
Me t h o d s : Pregnant female mice were orally administered with either vehicle (peanut oil) or 3 or 
6 mg/kg CPF on gestational day (GD) 15 to GD18, and offspring were treated subcutaneously 
with either vehicle or 1 or 3 mg/kg CPF on postnatal days (PNDs) 11 to PND14. Dose levels were 
chosen to avoid systemic toxicity and inhibition of brain acetylcholinesterase. Offspring were sacri-
ficed at 5 months of age, and expression of OT, AVP, and PRL was analyzed in the hypothalamus 
by Western blot or enzyme-linked immunosorbent assay (ELISA) analysis.
re s u l t s : Both male and female mice showed dose-related enhancement of OT expression, with 
males presenting the more intense effect. AVP expression was significantly reduced in male mice 
at the higher prenatal and postnatal dose. We observed no significant effect on PRL expression in 
either sex. Overall, outcomes were mainly attributable to fetal exposure, whereas postnatal doses 
appeared to potentiate the prenatal effects.
co n c l u s i o n s : Our data indicate that developmental exposure to CPF may permanently interfere 
with specific key signaling proteins of the hypothalamic peptidergic system, with time-, dose-, and 
sex-related effects still evident at adulthood.
ke y w o r d s : arginine vasopressin, developmental neurotoxicity, endocrine disruptors, organophos-
phorus insecticides, oxytocin, prolactin. Environ Health Perspect 117:112–116 (2009).  doi:10.1289/
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immune system, and so forth (Bole­Feysot 
et al. 1998; Cooke et al. 2004); however, 
hypothalamic PRL synthesis is independent 
from the anterior pituitary and is involved in 
the modulation of parental care, libido, and 
adaptive responses to stress (Bole­Feysot et al. 
1998; Cooke et al. 2004).
In our previous work on the behavioral 
effects of prenatal and/or postnatal CPF expo­
sure in mice (Ricceri et al. 2006), we evalu­
ated two different treatment windows, the late 
gestational phase [gestational day (GD) 15 to 
GD18] and the late neo  natal stage [postnatal 
day (PND) 11 to PND14], characterized by 
different central nervous system (CNS) matu­
rational events and representing critical phases 
of susceptibility to CPF action in rodents 
(Garcia et al. 2003). That study was designed 
to compare the effects of prenatal and/or post­
natal exposure to CPF doses within the range 
of fetal and childhood exposure (Gurunathan 
et al. 1998; Ostrea et al. 2002) on sexually 
dimorphic behaviors in adult mice. We found 
that CPF enhanced socio  agonistic behaviors 
in males and increased responsiveness to pups 
in virgin females (Ricceri et al. 2006). In addi­
tion, CPF tended to reduce anxiety levels, 
with females more affected than males. In the 
present study, on the basis of the behavioral 
evidence collected, we investigated whether 
the same CPF treatment schedule, in addition 
to inducing signifi  cant behavioral changes 
in exposed offspring, also had long­lasting 
effects on hypothalamic expression of OT, 
AVP, and PRL. To this end, male and female 
adult mice previously undergoing prenatal 
and/or postnatal exposure to CPF (Ricceri 
et al. 2006) were sacrificed at 5 months of 
age, and levels of OT, AVP, and PRL were 
evaluated in the hypothalamus by Western 
blot or enzyme­linked immunosorbent assay 
(ELISA) analysis.
We show here that developmental expo­
sure to CPF affects the constitutive protein 
levels of OT and AVP, with a more evident 
effect in males, whereas PRL is unaffected. 
These data suggest that CPF interferes with 
maturation of neuroendocrine regulation of 
sex­dimorphic behavioral patterns in rodents, 
and support the hypothesis that CPF may act 
as an EDC by altering the physiologic modu­
latory activity of neuro  hypophyseal hormones.
Materials and Methods
Animals and treatments. All experiments 
on animals were performed with regard for 
alleviation of suffering, in accordance with 
European Council Directive 86/609/EEC 
(European Economic Community 1986) 
and the Italian legislation on animal experi­
mentation. The experimental schedule has 
been described in detail previously (Ricceri 
et al. 2006). We used 30 pregnant CD1 mice: 
10 vehicle controls, 10 treated with 3 mg/kg 
CPF (CPF3), and 10 treated with 6 mg/kg 
CPF (CPF6). Briefly, pre  natal CPF (Chem 
Service, Inc., West Chester, PA, USA), dis­
solved in peanut oil vehicle, was adminis­
tered to pregnant females by intra  oral gavage 
[volume, 0.1 mL/kg body weight (bw)] from 
GD15 to GD18 (CPF3 or CPF6). Control 
animals received similar vehicle administra­
tion on the same schedule. Within each of 
the 30 litters (culled at birth to the standard 
size of eight pups), we treated six pups by 
subcutaneous injection in the nape of the 
neck from PND11 to PND14: one male and 
one female were randomly assigned to receive 
vehicle, one male and one female to receive 
CPF 1 mg/kg (CPF1), and one male and one 
female to receive CPF3 treatment (split­lit­
ter design). This established nine treatment 
groups: M0P0, M0P1, M0P3, M3P0, M3P1, 
M3P3, M6P0, M6P1, M6P3, where M indi­
cates pregnant female treatment, P repre­
sents postnatal treatment to the newborn, 
and numbers correspond to the CPF dose 
in milli  grams per kilogram body weight per 
day administered prenatally (M dose) and/or 
postnatally (P dose). As a result, all the pups 
in a litter received the same prenatal treat­
ment but belonged to six different combina­
tions of postnatal treatment by sex. Whole 
litters were weaned on PND23, maintained in 
same­sex pairs, and left undisturbed until the 
start of the behavioral studies (2 months). At 
5 months of age, nine females and nine males 
from each of the nine treatment groups were 
sacrificed by decapitation, and hypothalami 
were excised and frozen for protein analysis.
Sample preparation. Mouse hypothalami 
were lysed in 100 µL lysis buffer (20 mM 
Tris­HCl, pH 7.4; 150 mM NaCl; 5 mM 
EDTA; 1% nonyl phenoxy polyethoxy 
ethanol, supplemented with 1 mM phenyl­
methylsulfonylfluoride) and homogenized 
with a 2­mL sterile syringe. After a 1­hr 
incubation on ice, lysates were centrifuged at 
13,000 rpm, 4°C, for 20 min; two or three 
supernatants per treatment (depending on the 
size) were pooled together to obtain sufficient 
protein content. We determined protein con­
centration with the Bio­Rad Protein Assay 
(Bio­Rad, Hercules, CA, USA) using bovine 
serum albumin as standard (Sigma­Aldrich, 
St. Louis, MO, USA).
Western blot analysis. We separated 50 µg 
total extract proteins per lane into 10% Bis­
Tris NuPAGE Novex precast gels (Invitrogen, 
Carlsbad, CA, USA) using the pre  stained 
Novex Sharp protein standards as molecular 
markers (Invitrogen). The gel was then elec­
troblotted onto a PVDF polyvinyl difluoride 
membrane (Bio­Rad) by semidry Trans­Blot 
(SciePlus, Southam, Warwickshire, UK). 
The blotted membranes were then washed 
with phosphate­buffered saline (PBS) and 
blocked overnight with a 5% nonfat dry 
milk solution (Bio­Rad). After washing with 
PBS containing 0.1% Tween 20 (PBST), 
we incubated the membranes 1.5 hr at room 
temperature (RT) with a polyclonal anti­PRL 
(Santa Cruz Biotechnology, Santa Cruz, CA, 
USA) or anti­AVP antibody (Chemicon, 
Temecula, CA, USA; < 1% cross­reactivity 
with OT), in PBS containing 5% nonfat dry 
milk. After washing with PBST, we incu­
bated the membranes 1 hr at RT with the 
appropriate horse  radish peroxidase (HRP)–
conjugated secondary antibody (Santa Cruz 
Biotechnology) diluted in PBS containing 
5% nonfat dry milk. The blots were visualized 
using a Western Blotting Luminol Reagent 
(Santa Cruz Biotechnology) and a VersaDoc 
Imaging System (Bio­Rad). We performed 
band densitometry with the Quantity One 
software, version 4.6.3 (Bio­Rad).
ELISA analysis. For each treated pooled 
lysate (described above), a solution of 50 µg/
mL total extract proteins in coating buffer 
(0.1 M NaCO3, 0.1 M NaHCO3, pH 9.5) 
was used to coat a 96­well flat­bottomed 
plate (100 µL/well) for 1 hr at 37°C and then 
overnight at 4°C. After a PBS wash, the wells 
were blocked 2 hr at RT with a 5% nonfat 
dry milk solution (Bio­Rad). Plates were then 
washed with PBST and incubated for 1.5 hr 
at RT with a monoclonal anti­OT antibody 
(Chemicon) diluted in PBS containing 5% 
nonfat dry milk (100 µL/well). After washing 
with PBST, we incubated plates 1 hr at RT 
with HRP­conjugated secondary antibody 
(Santa Cruz Biotechnology) diluted in PBS 
containing 5% nonfat dry milk (100 µL/well). 
Detection was performed with the TMB 
(tetra  methyl  benzidine) Peroxidase Substrate 
Kit (Vector Laboratories, Burlingame, CA, 
USA), reading absorbance at 450 nm with 
a Victor 3 Multilabel Reader (PerkinElmer, 
Shelton, CT, USA).
Statistical analysis. Data are presented as 
mean ± SE obtained from three assay determi­
nations for each treatment group for each sex. 
We conducted a preliminary global analysis of 
variance (ANOVA) including measurements 
of the three peptides using transformed data 
(percentages based on OT, AVP, and PRL lev­
els of the M0P0 group for each sex), with OT, 
AVP, and PRL levels considered as repeated 
measures in the same pool of hypothalami. We 
then performed separate ANOVAs for each 
neuro  peptide incorporating all contributing 
variables: prenatal (0, 3, and 6) and postnatal 
(0, 1, and 3) treatments, as well as sex. We 
used Tukey’s honestly significant difference 
test for post hoc comparisons.
Results
CPF, at the dose levels used in this study, did 
not elicit systemic toxicity or weight loss in 
pregnant females, nor did we find any signifi­
cant changes in fetal viability, weight of pups Tait et al.
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at birth, general growth, or maternal care (data 
not shown). We observed no signs of cholin­
ergic intoxication at 1 and 6 hr after injection 
on PND11–PND14, and brain AChE activ­
ity of exposed pups was unaffected by either 
prenatal or postnatal CPF treatment (data not 
shown; for brain AChE activity values, see 
Ricceri et al. 2006).
The preliminary global analysis revealed 
a main effect of neuropeptide [F(2,36) = 
89.85, p < 0.0001] and significant prenatal 
CPF × neuropeptide and postnatal CPF × 
neuro  peptide interactions [F(4,36) = 23.33, 
p < 0.0001; and F(4,36) = 2.66, p = 0.0482, 
respectively], thus confirming that OT, AVP, 
and PRL were differentially affected by CPF 
treatment and that separate analyses must be 
performed.
OT. Overall, CPF exposure resulted in sig­
nificant dose­related increase of OT expression 
(Figure 1A). The global ANOVA revealed a 
significant main effect of the prenatal treat­
ment [F(2,36) = 8.48, p < 0.01]. Post hoc 
comparisons showed that OT levels were sig­
nificantly higher in the CPF6­treated group 
than in the vehicle­treated group (p < 0.01; 
Figure 1A). As for post  natal CPF treatment, 
we found no significant effect and only a trend 
toward increased OT levels in the M6P3 group 
(Figure 1A). We also found a significant main 
effect of sex [F(1,36) = 12.72, p < 0.01]. Thus, 
to obtain information on different impacts of 
CPF in the two sexes, we performed separate 
analyses in males and females. The main effect 
of prenatal CPF was significant only in males 
[F(2,18) = 6.25, p < 0.01; Figure 1B]. Post hoc 
comparisons showed a significant difference 
between the higher prenatal dose, CPF6, and 
the vehicle­treated groups (p < 0.01).
AVP. Overall, we found a dose­depen­
dent decrease in AVP expression in the hypo­
thalamus after CPF treatment (Figure 2A). 
The global ANOVA yielded a main effect 
of pre  natal CPF treatment [F(2,27) = 7.25, 
p < 0.01], whereas the post  natal treatment 
effect was not significant. We also found a sig­
nificant effect of sex [F(1,27) = 6.25, p < 0.01]. 
AVP expression was markedly reduced in male 
mice exposed prenatally to CPF6. Post hoc 
comparisons performed on the interaction sex 
× pre  natal × post  natal treatment [F(4,36) = 
3.49, p < 0.01] showed that the hypothalamic 
levels of AVP were significantly decreased in 
M6P3 males (Figure 2B; p < 0.05). The effect 
of either prenatal or postnatal CPF was not 
significant in females, although a general ten­
dency toward a decrease in AVP expression 
with increasing doses was apparent.
PRL. Analysis of PRL protein expression 
did not reveal any significant effect after CPF 
exposure (either prenatal or postnatal) in both 
sexes. We noted an overall higher expression 
in females, but without any influence of the 
treatment (Table 1).
Discussion
The present findings indicate that developmen­
tal exposure to subtoxic CPF doses within the 
range of human fetal or neonatal exposures has 
long­term effects on the hypothalamic protein 
levels of OT and AVP of mice at adulthood. 
Specifically, we found evidence for a long­
lasting, dose­related increase in hypothalamic 
OT expression after prenatal and postnatal 
CPF exposure. AVP expression was affected to 
a lower extent, showing a consistent decrease 
only at the higher pre­ and postnatal dose, 
M6P3, and selectively in the male sex. By con­
trast, no change in PRL expression was evident 
after CPF exposure at any dose level. Hence, 
developmental exposure to CPF induced a 
dose­, timing­, and sex­related increase of 
OT and decrease of AVP, without affecting 
PRL. Such outcomes are largely attributable to 
fetal (GD15–GD18) exposure to CPF at the 
highest dose of 6 mg/kg bw, although post­
natal exposure (PND11–PND14) appears to 
potentiate the prenatal effects. To the best of 
our knowledge, this is the first study showing 
that CPF given during early phases of CNS 
develop  ment affects the constitutive levels of 
hypothalamic neuropeptides with a double 
role of neurohypophyseal hormones and 
neuro  transmitters.
Our results indicate that both the timing 
of exposure and the dose level are critical for 
the developmental toxicity of CPF. Overall, 
the fetal phase emerges as the most critical 
window, with late neonatal phase contributing 
only at the highest exposure. The mouse hypo­
thalamus becomes delineated by GD11, SON 
is defined from GD13, and PVN appears a 
day later, whereas the secretory activity of 
the hypothalamus­neurohypophysis system 
begins on GD18 (Karim and Sloper 1980). 
Figure 1. Effect of prenatal and postnatal CPF exposure on OT expression in mice. (A) Main effect of CPF exposure on OT peptide expression, with a significant dif-
ference (p < 0.01) between prenatal vehicle and 6 mg/kg bw CPF. (B) CPF effect on OT expression in male and female mice, with a significant difference (p < 0.01) 
in males between 6 mg/kg bw and vehicle-treated groups. Data are mean ± SE absorbance units read at 450 nm.
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In our experiments, CPF gestational exposure 
spanned GD15–GD18, thus including the 
critical developmental window for SON and 
PVN neuronal precursors; as a consequence, 
the capacity for neuro  peptide synthesis could 
be persistently affected. Notably, in rats, late 
gestational exposure to CPF (GD17–GD20) 
resulted in more disruption to brain function­
ality than did exposure during neurulation 
(GD9–GD12), with males more affected than 
females (Aldridge et al. 2005b).
Our results also indicate that postnatal 
exposure to 3 mg/kg bw CPF further enhanced 
the effect of the prenatal exposure and was 
more evident in male mice. Both oxytocinergic 
and vasopressinergic systems undergo signifi­
cant postnatal changes in rodent brain; OT­ 
and AVP­containing neurons increase with age 
in a similar rate for both sexes but differ in the 
timing of maturation. In fact, on PND1, there 
are more AVP­ than OT­immunoreactive 
neurons; the main increase in AVP is between 
PND1 and PND8, whereas OT rises mostly 
during PND8–PND21 (Yamamoto et al. 
2004). We carried out postnatal treatments 
on PND11–PND14, corresponding to a key 
develop  ment stage for the oxytocinergic sys­
tem and a steady developmental stage for the 
vasopressinergic system; in fact, the oxytocin­
ergic system was particularly affected after CPF 
exposure, whereas the vasopressinergic system 
was modulated only by the highest CPF dose. 
We must also consider that OT and AVP, 
differing by only two amino acids, may dis­
play some receptor cross­reactivity (Barberis 
and Tribollet 1996), thus potentially interact­
ing during critical developmental phases. In 
fact, in a recent study carried out in prairie 
voles, manipulation of OT levels on PND1 
was associated with long­lasting regional pat­
terns of change in the AVP (V1a) receptor 
system, but only in males (Bales et al. 2007). 
Therefore, if CPF is able to interfere with the 
OT synthesis in PVN and SON hypothalamic 
neurons during critical developmental win­
dows, it is also possible that such disruption, 
in turn, could have repercussions on the AVP 
system as well, with males more vulnerable 
than females. Finally, we cannot exclude that 
the effects on neuro  hypophyseal hormones are 
mediated by changes in serotonergic neuro­
transmission induced by CPF, previously 
described in rodents exposed to CPF as in the 
present experimental schedule (Aldridge et al. 
2003; Slotkin and Seidler 2005).
We also assessed hypothalamic PRL and 
found it unaltered by CPF exposure. PRL 
belongs to a different hormone family than does 
OT and AVP, which derive from the same gene 
(Gimpl and Fahrenholz 2001). Moreover, PRL 
regulation follows more complex pathways not 
yet fully described (Cooke et al. 2004). In addi­
tion, our results in mice are consistent with pre­
vious observations showing higher hypothalamic 
PRL levels in females than in male rats because 
of the regulatory action of estradiol on brain 
PRL (Ben­Jonathan et al. 1996). We cannot 
exclude that prenatal and/or postnatal exposure 
to CPF elicited some reversible effect on PRL 
expression in mouse hypothalamus that was 
restored through feedback mechanisms at the 
time of our observation. However, our results 
suggest an alteration of specific neuropeptide 
pathways, rather than the general effect of a 
chemical, such as an OP insecticide, interfering 
with neuronal signaling.
These results lead us to reconsider the sex­
dimorphic behavioral alterations observed 
after CPF exposure in the same set of mice 
(Ricceri et al. 2006). A point­to­point cor­
relation between behavioral changes and OT 
and AVP levels is unfeasible, because in the 
present study we analyzed protein expres­
sion on tissue pools from individuals of the 
same experimental group. Nonetheless, the 
possible implication of OT and AVP in the 
sex­dimorphic behavioral outcomes previ­
ously observed deserves some attention. In 
particular, we found remarkable hyperactivity 
in the open­field test in male mice after pre­
natal CPF exposure, either with or without 
an associated postnatal treatment. Moreover, 
CPF enhanced agonistic responses toward an 
unfamiliar male both in juvenile and in adult 
male mice. All effects in males were more 
marked in the highest­exposure, M6P3 group 
(Ricceri et al. 2003, 2006). AVP has a key 
role in regulating aggressive behavior in male 
mice: a recent study, using a mouse model 
of early life stress, found an inverse correla­
tion between hypothalamic AVP levels and 
aggressive behavior in adult males (Veenema 
et al. 2007). Moreover, several pieces of evi­
dence indicate the 5­HT system as the key 
regulator of the aggressive behavior in males 
(Bell and Hobson 1994; Simon et al. 1998); 
the impairment caused by CPF exposure in 
such regulatory system, particularly marked 
in males (Aldridge et al. 2004), is in agree­
ment with our behavioral observations. In 
this respect, it is worth noting that a complex 
interaction among 5­HT, AVP, and OT has 
been documented in the hypothalamus of 
selected mouse and rat strains, as well as in 
transgenic mouse models, thus indicating an 
important role of such a signaling network in 
the modulation of social responses, including 
aggressive and affiliative behaviors (Vacher 
et al. 2002; Veenema and Neumann 2007; 
Wersinger et al. 2007).
Virgin female mice were more responsive 
to pups after postnatal CPF exposure (Ricceri 
et al. 2006). The responsiveness of nulliparous 
females toward pups is correlated to noradren­
ergic inputs in olfactory areas, independent 
from normal hormone regulation (Thomas 
and Palmiter 1997). Most mammals respond 
on an olfactory basis in taking care of pups; 
because the development of the olfactory 
memory in rodents is critically dependent on 
OT and AVP systems (Bielsky and Young 
2004), the enhanced expression of hypotha­
lamic OT could be a plausible factor in the 
abnormal CPF­induced onset of maternal 
behavior. In fact, it has been shown in rats that 
OT dosing triggers/elicits maternal behavior 
(Gimpl and Fahrenholz 2001; Kendrick et al. 
1997). Finally, CPF­exposed rodents of both 
sexes showed reduced anxiety levels, spending 
more time in the open arms during plus­maze 
performance (Aldridge et al. 2005a; Ricceri 
et al. 2006). Such effect could be also related 
to OT increase, because this neuropeptide 
exerts a stress­reducing action in female mice 
(Gimpl and Fahrenholz 2001), where both 
hypothalamic and amygdaloidal OT receptors 
modulate anxiety levels (Bale et al. 2001).
It is currently difficult to fully assess the 
potential impact, if any, of the CPF­induced 
altered OT and AVP expression in hypothal­
amus, because these two neuro  peptides are 
involved in many central behaviors, including 
sexual and parental ones, mediated by multiple 
CNS pathways. Further studies are necessary 
to evaluate potential alterations of oxytociner­
gic and vasopressinergic systems in other brain 
areas (amygdala, olfactory areas), including 
modulation in receptors expression and func­
tion, and their correlation with behavior.
In conclusion, our results demonstrate 
a specific, long­term impact of CPF on 
two neuropeptides having a critical role in 
behavioral processes, and confirm that late­ 
gestational/  early­prenatal CPF exposure leads 
to permanent gender­related effects also in 
mice (Aldridge et al. 2004; Dam et al. 2000; 
Garcia et al. 2003; Levin et al. 2001, 2002; 
Qiao et al. 2003, 2004). Furthermore, these 
results suggest a possible neuro  endocrine 
mechanism underlying some of the sex­ 
selective behavioral effects reported in the 
literature after perinatal CPF exposure, which 
points to a greater vulnerability of the male 
sex, more evident in later developmental 
stages (Aldridge et al. 2005a; Dam et al. 2000; 
Levin et al. 2001). Sex­dependent differences 
can indeed be a major issue in the hazard 
Table 1. Effect of CPF exposure on PRL expression 
in male and female mice.
Treatment  Males  Females
M0P0  30.43 ± 0.32  29.73 ± 5.84
M0P1  28.01 ± 2.63  34.49 ± 3.07
M0P3  31.10 ± 1.34  30.51 ± 3.39
M3P0  29.16 ± 1.00  37.93 ± 6.83
M3P1  27.39 ± 0.82  35.17 ± 2.16
M3P3  33.47 ± 2.58  35.91 ± 0.49
M6P0  34.99 ± 3.76  31.62 ± 1.90
M6P1  33.14 ± 4.45  29.77 ± 3.84
M6P3  28.84 ± 2.41  32.64 ± 2.43
Values are optical density × mm2 levels ± SE as determined 
by electrophoresis gel densitometry. ANOVA did not reveal 
any significant difference among CPF treatment groups.Tait et al.
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characterization of chemicals interfering with 
neuro  endocrine pathways (Calamandrei et al. 
2006). It is worth noting that OT and AVP 
have been implicated in autism and autism 
spectrum dis  orders, with a sex­related pat­
tern (Carter 2007). Thus, social as well as 
anxiety­related behaviors might be additional 
sensitive targets of risk factors altering OT 
and AVP.
In addition, our data lend further sup­
port to CPF being considered an EDC, 
albeit with specific mechanisms and targets. 
Other OP insecticides could exert similar 
effects and should be further investigated 
at the hypothalamic–pituitary–adrenal axis 
level. Therefore, neuroendocrine effects, espe­
cially in susceptible developmental windows, 
deserve more attention in the risk assessment 
of OP insecticides.
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